Search our team at AdventHealth Research Institute
-
NCT04998747
A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)
This study is not currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Clinical Cancer ResearchParticipants who have have relapsed (returning) and refractory (stopped responding to treatment) multiple myeloma (RRMM) will be invited to take part in this study. This study is being done to learn...
-
NCT05346835
68284528MMY4006 EAP: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
This study is currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, Florida -
NCT04071457
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchPatients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first...
-
NCT06238479
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Clinical Cancer ResearchYou are being invited to take part in this study because you have been diagnosed with a type of cancer that may express a protein called nectin-4, which LY4101174 is designed to treat and you have...
-
NCT05948865
CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of the study, called CPO301-US-101, is to see if CPO301 (also known as SYS6010) is safe and effective in treating your type of cancer when administered as an intravenous (administered into...
-
NCT04669899
Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
This study is not currently enrolling.Associated Conditions: Multiple MyelomaResearch Area: Clinical Cancer ResearchA medical research study for participants who have been diagnosed with a solid tumor (i.e. cancer) and currently, the tumor is unresponsive to approved treatments, approved treatments are worsening...